Table 1.
Immunohistochemical analysis of CTSL, 53BP1, and VDR expression in sporadic human breast cancer
| Proteins | Molecular type | H score | Kruskal-Wallis test p-value | ||
| Mean (SD) | Median [P25, P75] | Min–Max | |||
| Cytoplasmic CTSL | Luminal A | 137 (36.6) | 135 [110,160] | 50–205 | 0.50 |
| Luminal B | 134 (35.2) | 130 [110,155] | 75–-230 | ||
| Erbb2 (−1) | 141 (43.1) | 135 [110,171] | 50–230 | ||
| Triple negative (−1) | 145 (35.2) | 140 [120,175] | 80–200 | ||
| Nuclear CTSL | Luminal A | 8 (18.0) | 0 [0, 0] | 0–90 | <0.0001 |
| Luminal B | 8 (14.9) | 0 [0, 15] | 0–75 | ||
| Erbb2 (−1) | 9 (18.3) | 0 [0, 5] | 0–75 | ||
| Triple negative (−1) | 42 (44.3) | 30 [0, 83] | 0–125 | ||
| 53BP1 | Luminal A | 155 (56.5) | 160 [120, 200] | 0–270 | 0.0002 |
| Luminal B | 150 (45.8) | 150 [120, 170] | 40–280 | ||
| Erbb2 (−4) | 154 (58.1) | 150 [110, 200] | 20–300 | ||
| Triple negative | 112 (44.4) | 105 [80, 143] | 0–190 | ||
| Cytoplasmic VDR | Luminal A (−4) | 50 (50.9) | 50 [0, 90] | 0–185 | 0.22 |
| Luminal B (−4) | 52 (50.8) | 50 [0, 80] | 0–190 | ||
| Erbb2 (−2) | 53 (48.8) | 50 [0, 95] | 0–160 | ||
| Triple negative (−3) | 69 (50.6) | 50 [20, 110] | 0–170 | ||
| Nuclear VDR | Luminal A (−4) | 121 (68.2) | 110 [100, 170] | 0–300 | 0.78 |
| Luminal B (−4) | 125 (65.2) | 130 [90, 160] | 0–300 | ||
| Erbb2 (−2) | 122 (73.3) | 125 [95, 160] | 0–300 | ||
| Triple negative (−3) | 114 (62.3) | 110 [80, 150] | 0–270 | ||
Values are mean and median Hscores for nuclear and cytoplasmic CTSL, 53BP1, and VDR per tumor type. Min–Max denotes minimal and maximal values within the tumor subtype. Dispersion is assessed by SD and percentiles 25 and 75 ([P25, P75]); (−X) represents X missing values per molecular type as a result of insufficient specimen. Bolded Hscore values highlight the molecular subtype responsible for the statistically significant difference identified with the Kruskal-Wallis test that compares all molecular types (bold p-value if significant difference).